Advances in thalidomide therapy for idiopathic myelofibrosis.
- Author:
Li SONG
1
;
Jia-Lin CHEN
Author Information
1. Department of General Internal Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
adverse effects;
therapeutic use;
Humans;
Immunosuppressive Agents;
adverse effects;
therapeutic use;
Primary Myelofibrosis;
drug therapy;
Thalidomide;
adverse effects;
therapeutic use;
Treatment Outcome
- From:
Acta Academiae Medicinae Sinicae
2009;31(5):651-653
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic myelofibrosis a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibrosis.
